Trial Profile
A single-center, open-label, randomized study of the pharmacokinetics of Azasite [azithromycin] ophthalmic solution versus Vigamox [moxifloxacin] in the tears of healthy volunteers following a single ocular administration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary) ; Moxifloxacin
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 08 Dec 2009 Additional lead trial centre and Merck as company identified as reported by ClinicalTrials.gov.
- 18 Sep 2009 Planned number of patients changed from 36 to 37 as reported by ClinicalTrials.gov.
- 13 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.